By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Protagonist Therapeutics 

7707 Gateway Boulevard
Suite 140
Newark  California   94560  U.S.A.
Phone: 650-587-5766 Fax: n./a


Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, lower cost, and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.




Founder: Mark Symythe

CEO: Dinesh Patel

CMO (Marketing): Richard Shames

CFO: Tom O’Neil

CSO (Scientific): David Liu


Please click here for Protagonist Therapeutics job opportunities.


Please click here for clinical trial information.

Key Statistics

Ownership: Public

Web Site: Protagonist
Symbol: PTGX


Company News
Protagonist (PTGX) Announces Preliminary Phase I Study Results With Novel Hepcidin Mimetic, PTG-300 9/20/2017 6:14:34 AM
Protagonist (PTGX) Announces Closing Of Janssen Pharmaceutical License And Collaboration Agreement For PTG-200 And Receipt Of $50 Million Payment 8/25/2017 6:45:56 AM
Protagonist (PTGX) Reports Second Quarter 2017 Financial Results And Business Highlights 8/9/2017 12:36:56 PM
Protagonist (PTGX) Appoints Five Prime (FPRX) CEO, Lewis T. "Rusty" Williams, To Its Board Of Directors 6/8/2017 8:06:01 AM
Can Protagonist (PTGX) Stock Still Double After Its Huge Gain? 5/31/2017 6:00:06 AM
Protagonist (PTGX) Initiates Phase l Study with Novel Hepcidin Mimetic, PTG-300 5/25/2017 6:29:54 AM
Protagonist (PTGX) Receives $1.34 Million SBIR Funding For Development Of Biomarkers Of IL-23 Receptor Antagonist Activity 5/24/2017 7:01:11 AM
Protagonist (PTGX) Reports First Quarter 2017 Financial Results 5/11/2017 8:37:25 AM
Key Patent Issues Covering Protagonist (PTGX)' Oral Peptide IL-23 Receptor Antagonists, Including The Development Candidate PTG-200 5/5/2017 7:45:56 AM
Protagonist (PTGX) Reports Fourth Quarter And Year-End 2016 Financial Results 3/8/2017 11:26:24 AM